Page 2 - Jay Bradner News Today

The FDA has approved tarlatamab, a novel bispecific T-cell engager, to treat patients with extensive-cell small cell lung cancer (SCLC).

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor

FRIDAY, MAY 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer.

The FDA cleared the Amgen drug, called Imdelltra, as a treatment for patients with advanced small-cell lung cancer.

The Food and Drug Administration approved Imdelltra (tarlatamab) for the treatment of patients with advanced small cell lung cancer that progressed on or after a platinum-based chemotherapy.

Amgen Inc. won US approval for a new drug to treat a particularly aggressive form of advanced lung cancer, providing a badly needed new option for patients when chemotherapy stops working.

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the...

As the demand for obesity drugs continues to surge, biopharma companies are eagerly seizing the opportunity to capitalize on the trend.

MariTide, formerly AMG 133, is an injectable form of drug targeting two gut hormones — gastric inhibitory polypeptide receptor, or GIP, and glucagon-like peptide 1, or GLP-1.

(CTN News) - In a statement on Thursday, Amgen said it will stop developing an experimental weight loss pill in favor of its injectable..................